0
Views
0
CrossRef citations to date
0
Altmetric
Plain Language Summary

Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer: a plain language summary of the DESTINY-Lung01 study

Received 20 Oct 2023, Accepted 10 May 2024, Published online: 16 Jul 2024

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

For more information please visit our Permissions help page.